Intervention

Nivolumab + Relatlimab

ClinicalTrials.gov intervention label

Clinical trials1

Recruiting1

Common conditions11

Lead sponsors shown1

Clinical trials

1 shown

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483 · 2021-12-14

RECRUITING

Common conditions

Clear Cell Renal Cell Carcinoma (ccRCC)1 Colorectal Cancer (CRC)1 Drug-Drug Interaction (DDI)1 Head and Neck Squamous Cell Carcinoma (HNSCC)1 Hepatocellular Carcinoma (HCC)1 Metastatic Castration-Resistant Prostate Cancer (mCRPC)1 Non-Clear Cell Renal Cell Carcinoma (nccRCC)1 Non-small Cell Lung Cancer (NSCLC)1 Renal Cell Carcinoma (RCC)1 Solid Tumor1 Urothelial Carcinoma (UC)1

Leading sponsors

Exelixis1

Trial status mix

RECRUITING1

Phase mix

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.